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Abstract: Objective: The purpose of the
present study was to investigate the effects of
the presence of hypersplenism, antiplatelet
antibody and anticardiolipin antibody, which
are thought to be important factors, on the
development of thrombocytopenia in patients
with cirrhosis with viral etiology.
Methods: This study includes 44 patients
with cirrhosis related to HBV and HCV, and
12 healthy control subjects. Spleen size was
evaluated by ultrasonography, the presence of
antiplatelet antibody by flow cytometry, and
IgG and IgM isotypes of anticardiolipin antibody by enzyme immunoassay.
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Results: There was a significant difference in
ultrasonographic spleen size between the
patients with and without thrombocytopenia
(p<0.05). The presence of antiplatelet antibody was demonstrated in 19 patients (43%)
with cirrhosis, whereas none of the control

Introduction
Thrombocytopenia due to liver disease and portal
hypertension is a well-recognized finding and its prevalence in cirrhosis varies from 15 to 55% (1). The mechanisms responsible for thrombocytopenia in cirrhosis
include hypersplenism, immune-mediated platelet
destruction and platelet production defect in bone marrow (e.g., synthesis abnormality of thrombopoietin and
nutrional folate deficiency). It is known that increased
sequestration of cells in the spleen due to splenomegaly is
only one of the causes of thrombocytopenia (2-4). It has
been suggested that the thrombocytopenia found in cirrhotic patients may be developed in the presence of antibodies to platelets and the resultant immune-mediated
platelet destruction or in the presence of anticardiolipin
antibodies as well as the existence of hypersplenism (37). The purpose of this study was to investigate the
effects of spleen size and the presence of anticardiolipin
antibodies (ACA) and of antiplatelet antibodies (APA) on

subjects had antiplatelet antibody. In our
study we found no relationship between the
presence of antiplatelet antibody and platelet
count or severity of thrombocytopenia. Of 31
patients with cirrhosis, six (19%) had anticardiolipin antibody. There was no relationship
between IgG and IgM isotypes and anticardiolipin antibody platelet count, presence and
severity of thrombocytopenia.
Conclusions: Our results support the idea
that spleen size is an important factor development of thrombocytopenia in patients with
cirrhosis with viral etiology. Antiplatelet antibody and anticardiolipin antibody are often
found in patients with cirrhosis. However, we
obtained no data regarding any role which
these antibodies play in the immune degradation of platelets.
Key Words: Cirrhosis, thrombocytopenia,
anticardiolipin antibody, antiplatelet antibody

the development of thrombocytopenia in cirrhotic
patients.

Material and Methods
Forty-four chronic liver patients with biopsy-proved
liver cirrhosis related to HBV (19 patients) or HCV (25
patients), and 12 healthy control subjects (seven males)
were studied. Criteria for inclusion in the study were as
follows: absence of a history of receiving therapy that
could suppress bone marrow, absence of a history of
blood transfusion during the past three months, absence
of a secondary disease except cirrhosis, or the use of a
drug that could affect coagulation parameters, and normal levels of serum B12 and folate. In our study, ChildPugh classification was used in all cirrhotic patients for
evaluation of the severity of the disease. Levels of serum
albumin and bilirubin, prothrombin time, the presence
and severity of ascites and encephalopathy were parame-
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ters for Child Pugh classification, and a compatible score
was given for each parameter. Each patient had a score
of between 5 and 15. A score below 7 was considered
Child-Pugh A, a score between 7-9 was Child-Pugh B and
a score above 9 was Child-Pugh C (8). The severity of
hepatocellulary dysfunction was assessed by Child-Pugh
classification with 12 being Child-Pugh A, 17 Child-Pugh
B, and 15 Child-Pugh C. Platelet count was measured
using a Coulter SKTS instrument. Thrombocytopenia was
defined as a platelet count below 150x103/µl. Platelet
count was made by automatic counter, but a peripheral
blood smear evaluation was made for every patient to
exclude miscount of platelets. Pseudothrombocytopenia
was excluded via peripheral smear evaluation.

well strip reader and results were calculated by a formula: adsorbance level/calibrator adsorbance level x calibrator concentration.

While antiplatelet antibodies were investigated in all
patients, anticardiolipin antibodies were evaluated in 31
of the 44 patients.

Statistical analysis was performed with the Pearson
product moment correlation test and StudentÕs t test as
appropriate. Data are expressed as mean ± standard
error of mean (SEM). A level of p<0.05 was considered
as significantly different.

The presence of antiplatelet antibodies in the cirrhotics and control subjects was studied by flow cytometry using goat anti IgG FITC, goat anti IgM FITC, antihuman CD41 FITC and mouse IgG1 FITC to demonstrate
nonspecific staining. The results were evaluated by flow
cytometry using a Becton Dickinson Facscalibur instrument. The cells in the lower right-hand position of the
diagram show the platelets contain anti IgG and anti IgM
antibodies, and the ratio of cells in this position was estimated by computer. The results were evaluated by flow
cytometry using a Becton Dickinson Facscalibur instrument (9-10).
Anticardiolipin antibody measurement was made via
enzyme immunoassay methods and cardiolipin was used
as an antigen in the test. The test was read on a multi-

Age (years)
Sex: Male (n)
Female (n)
Platelet (µL)
APA positive (n) (%)
Anticardiolipin antibody
Anticardiolipin antibody
Anticardiolipin antibody
Anticardiolipin antibody

IgG (GPL)
IgM (MPL)
IgG positive (n) (%)
IgM positive(n) (%)

Abdominal ultrasonographic studies were carried out
using a General Electric RT-x200 with a 3.5 MHz convex
probe. Spleen size was examined in the supine and right
lateral positions by measuring the longitudinal distance of
the spleen.

Results
Some demographic and clinical features of the patient
and control groups are shown in Table 1. Thrombocytopenia was detected in 91% of the 44 cirrhosis patients.
The platelet count in the patients (82.688 ± 5.201
platelets/µl) was significantly lower than that of the control subjects (255.333 ± 15.072 platelets/µl) (p<0.001)
Some important clinical characteristics of the patients
with cirrhosis are shown in Table 2. Positivity for APA
was found in 19 patients (43%), positivity for ACA of the
IgG in 6 (19%) and ACA of the IgM in 6 (19%). The control population did not demonstrate either positivity for

Patients
(n=44)

Controls
(n=12)

58+2
26
18
82688+5201***
19 (43)**
17+2**
8+2
6 (19)*
6 (19)

51+4
7
7
255333+15072
0 (0)
10+1
5+1
0 (0)
1 (8)

(Difference is significant:***p<0.001, **p<0.01, *p<0.05)
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The results of IgG and IgM examinations were determined quantitatively as GPL and MPL, respectively. The
positivity of IgG and IgM was defined as the values equal
to or greater than 23 GPL unit/ml and 11 MPL unit/ml,
respectively.

Table 1.

Some Demographic and Clinical
Features of the Patient and Control
Groups.
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Table 2.

Some Important Clinical Characteristics of the Patients with
Cirrhosis.
n

%

Etiology
HBV
HCV
Child-Pugh grade
A
B
C
Platelet count
<150x103/µml
>150x103/µl
Platelet count
<100x103/µl
100-150x103/µl
Antiplatelet antibody
Positive
Negative
Anticardiolipin antibody IgG
Positive
Negative
Anticardiolipin antibody IgM
Positive
Negative

19
25

43
57

12
17
15

27
39
34

40
4

91
34

31
9

71
20

19
25

43
57

6
25

19
81

6
25

19
81

APA or positivity for ACA of the IgG isotype, whereas one
control subject (8%) demonstrated positivity for ACA of
the IgM isotype. The proportion of positivity for APA and
positivity for ACA of the IgM isotype in the cirrhotics was
significantly different from those of the controls (p<0.01
for APA, and p<0.05 for ACA of the IgG). The mean values for ACA of the IgG were 17 ± 2 GPL in the patients
with cirrhosis and 10 ± 2 GPL in the control subjects. The
mean values for ACA of the IgM were 8 ± 2 MPL in the
patients with cirrhosis and 5 ± 1 MPL in the control subjects. There was a significant difference between the
patient group and the controls with regard to the level of
ACA of the IgG (p<0.05).
When the thrombocytopenic patient population was
divided into two subgroups according to platelet count
3
3
3
(<100x10 /ml and 100x10 -150x10 /ml), no significant
difference was observed between these two groups with
regard to the positivity of APA, ACA of the IgG and ACA
of the IgM, and the levels of serum IgG, IgA, IgM and
globulin. However, in the cirrhotic patients whose platelet
counts were below 100x103/ml, the average ultrasono-

graphic spleen size was found to be significantly greater
than that of other subgroup (15±3 cm. and 11±1 cm,
respectively; p<0.05).
Of the 44 patients with cirrhosis, 19 (43%) had positivity for APA. No significant correlation was found
between the positivity for APA in the cirrhotics and age,
platelet count, spleen size measured ultrasonographically,
the presence of splenomegaly or serum levels of globulin,
IgG, IgA and IgM. The mean Child-Pugh score in the
patients who had positivity for APA was significantly
greater than that of the patients without APA (9.4±0.5
and 7.7±0.4, respectively; p<0.05).
Of the 31 cirrhotic patients, 6 (19%) had positivity
for ACA of the IgG isotype. No significant correlation was
found between the positivity for ACA of the IgG or IgM
isotype and platelet count, the presence of ultrasonography-proved splenomegaly or the level serum total globulin (p>0.05). A positive linear correlation was observed
between the level of ACA of the IgG and the level of
serum IgG (p<0.05). Similarly, there was a positive linear
correlation between the level of ACA of the IgM and the
level of serum IgM (p<0.05).
When the cirrhotic patients were divided into three
groups according to the severity of hepatocellulary dysfunction by Child-Pugh classification, no significant difference was observed among these three groups with regard
to platelet count, and levels of APA, and ACA of the IgM
and IgG. The mean level of ACA of the IgG in Child-Pugh
A patients (11±2 GPL) was likely to be lower than in
Child-Pugh B and Child-Pugh C patients (21±4 and 18±3
GPL, respectively), and there was a weak correlation
between Child-Pugh A, Child-Pugh B and Child-Pugh C
patients (p=0.08).
No significant difference was found in platelet count
and levels of APA, and ACA of the IgG and IgM between
the patients with splenomegaly detected ultrasonically
and those without splenomegaly (p>0.05).

Discussion
Thrombocytopenia is a common laboratory finding in
subjects with cirrhosis. In these patients, hypersplenism is
considered the main factor in the development of thrombocytopenia (2-4). However, the fact that platelet lifespan in some cirrhotic patients has been demonstrated to
be markedly shortened in several platelet survival studies,
and that the high frequency of antiplatelet antibodies and
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antiphospholipid antibodies has been determined in cirrhotic patients, suggests that the immune-mediated
platelet destruction could be effective in the development
of thrombocytopenia, as well (3-7).
In this study, we aimed to investigate the effects of
factors, such as hypersplenism, the presence of
antiplatelet antibodies and anticardiolipin antibodies,
thought to be responsible for the development of the
thrombocytopenia, on the occurrence of thrombocytopenia.
In our study, spleen size measured by ultrasound was
used to study the effect of spleen volume on thrombocytopenia. We found a significant difference in the spleen
size measured by ultrasound between subjects with or
without severe thrombocytopenia. These findings are in
agreement with the studies indicating that spleen size and
increased splenic sequestration have an effect on the
development of thrombocytopenia (11-14).
It was demonstrated that 19 (43%) of the 44 cirrhotic patients had antiplatelet antibodies. Our finding
was in agreement with previous studies report the prevalence of APA to be 40-80% in cirrhotic patients (3, 5,
15). We also found a relationship between the presence
of APA and the Child-Pugh score, indicating the severity
of the disease, in our study. The level of sialic acid of the
components of platelet membrane in the patients with
chronic liver disease is lower in the cirrhotic subjects.
Therefore, a new antigenic process of changing develops
in the surface of the platelet membrane. It is claimed that
the changes in the level of sialic acid in the platelet membrane increases with the severity of disease and facilitates
the adherence of antibodies to the surface of the platelet
membrane (5, 16).
No significant correlation was found between positivity for APA and the levels of serum IgG, IgA and IgM.
Some controversial results have been reported about this
relationship. While it has been suggested, especially in
previous reports, that increased serum globulin and
immunoglobulin fractions are nonspecifically adsorbed to
the platelet membrane in cirrhotics (16-18), recently it
was reported that no relationship was found between
serum globulin and immunoglobulin fractions and the
presence of APA, and that previous findings were due to
a methodic problem resulting from measuring nonspecific antibodies to the platelet membrane (15). Our results
support this view. We believe that there was no relation-
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ship between the increase of polyclonal globulin observed
in the cirrhotic patients and the occurrence of APA.
In our study, the fact that no relationship was found
between the severity of thrombocytopenia and positivity
for APA seems to be a finding which supports the idea
that immune-mediated platelet destruction has no role in
the development of the thrombocytopenia. Other possibilities may include failure of production response in bone
marrow to immune-mediated platelet destruction and
further impairment of reticuloendothelial system function
in these patients (20-21).
It has been suggested that the major determinant of
the fact that APA may lead to platelet destruction is the
functions of the reticuloendothelial system in the subjects
(23-24). It is known that the functions of the reticuloendothelial system are markedly impaired according to the
severity of the disease in cirrhotic patients (2-3, 25).
Impaired reticuloendothelial system function may also be
a factor which prevents the clearence of the platelets
from circulation. Our findings demonstrate that patients
with positivity for APA had higher Child-Pugh scores (i.e.,
had more severe hepatocellulary dysfunction) than those
without APA, and so it is indicated indirectly that these
patients with APA would have markedly impaired reticuloendothelial system function. The main reason that there
was no difference in platelet count between the patients
with and without APA may be the marked impairment of
reticuloendothelial system function in patients with APA.
In our study, six (19%) of the 31 cirrhotic patients
evaluated for ACA had positivity for ACA. The level of
ACA of the IgG in the cirrhotic patients was significantly
higher than that of the controls.
A statistically significant correlation was found in our
study between ACA of the IgG and serum level of IgG, and
between ACA of the IgM and serum level of IgM. According to a hypothesis that describes the occurrence of ACA
in the cirrhotic patients, the activation of polyclonal B cell
in these cases triggers the occurrence of ACA (26).
Another factor which determines the subtype of ACA in
the cirrhotics may be the increasing fraction of serum
immunoglobulin.
No significant correlation was found between the
presence of ACA of the IgG and ACA of the IgM, and
platelet count, and presence and severity of thrombocytopenia. The prevalence of the thrombocytopenia has
been reported to be from 10-40% in the cases with pos-
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itivity for ACA (21, 27-30). In some published studies, it
has been reported that the binding of ACA to the platelets
is not associated with the occurrence of thrombocytopenia, and that the major factor determining the platelet
count in cases with ACA is the balance between production and clearence of the platelets, and this picture was
defined as a compensated thrombocytolytic situation (2022).
In conclusion, our study supports the idea that the
spleen size was an effective factor in the development of

thrombocytopenia in patients with cirrhosis with viral etiology. Splenic sequestration probably increases in patients
with splenomegaly. Although ACA and APA are frequently found in cirrhotic patients, we did not obtain enough
data indicating that these two kinds of antibody play a
role in immune-mediated platelet destruction. In order to
elucidate the effects of these antibodies in the development of the thrombocytopenia in chronic liver patients,
new studies including thrombopoietin, an effective
growth factor in the production of the platelets, and
platelet kinetic, are necessary.
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